Compare Stocks: ONCY, LXEO, DMAC, and IPSC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$7.11 +6.9%	$6.61	$4.63 ▼ $10.42	$383.09M	1.01	204,242 shs	116,669 shs
IPSC Century Therapeutics	$2.04 +2.8%	$2.21	$0.44 ▼ $3.04	$367.01M	1.57	1.45 million shs	328,489 shs
LXEO Lexeo Therapeutics	$4.81 +3.8%	$4.62	$3.99 ▼ $10.99	$377.29M	1.46	948,672 shs	948,421 shs
ONCY Oncolytics Biotech	$0.81 +0.4%	$0.86	$0.73 ▼ $1.51	$96.20M	1.13	1.33 million shs	543,290 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	-1.48%	+1.99%	-13.30%	+5.22%	+42.40%
IPSC Century Therapeutics	-1.00%	0.00%	-12.00%	-13.54%	+290.30%
LXEO Lexeo Therapeutics	-3.74%	+10.24%	-3.94%	-18.77%	+2.21%
ONCY Oncolytics Biotech	+0.04%	+3.59%	-9.52%	-11.13%	-6.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$7.11 +6.9%	$6.61	$4.63 ▼ $10.42	$383.09M	1.01	204,242 shs	116,669 shs
IPSC Century Therapeutics	$2.04 +2.8%	$2.21	$0.44 ▼ $3.04	$367.01M	1.57	1.45 million shs	328,489 shs
LXEO Lexeo Therapeutics	$4.81 +3.8%	$4.62	$3.99 ▼ $10.99	$377.29M	1.46	948,672 shs	948,421 shs
ONCY Oncolytics Biotech	$0.81 +0.4%	$0.86	$0.73 ▼ $1.51	$96.20M	1.13	1.33 million shs	543,290 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	-1.48%	+1.99%	-13.30%	+5.22%	+42.40%
IPSC Century Therapeutics	-1.00%	0.00%	-12.00%	-13.54%	+290.30%
LXEO Lexeo Therapeutics	-3.74%	+10.24%	-3.94%	-18.77%	+2.21%
ONCY Oncolytics Biotech	+0.04%	+3.59%	-9.52%	-11.13%	-6.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	2.60	Moderate Buy	$12.00	73.41% Upside
IPSC Century Therapeutics	2.43	Hold	$4.75	144.22% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	293.08% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$8.50	953.28% Upside

Current Analyst Ratings Breakdown

Latest ONCY, LXEO, DMAC, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	DMAC DiaMedica Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	IPSC Century Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/25/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $9.00
6/11/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.08 per share	N/A
IPSC Century Therapeutics	$109.16M	3.21	$0.01 per share	150.38	$1.82 per share	1.07
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$32.77M	-$0.71	N/A	N/A	N/A	N/A	-77.15%	-69.23%	8/11/2026 (Estimated)
IPSC Century Therapeutics	-$9.58M	-$1.14	N/A	N/A	N/A	N/A	-49.89%	-37.42%	8/13/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.45	N/A	N/A	N/A	N/A	-47.48%	-41.72%	8/13/2026 (Estimated)
ONCY Oncolytics Biotech	-$28.76M	-$0.31	N/A	N/A	N/A	N/A	-2,185.97%	-321.54%	8/14/2026 (Estimated)

Latest ONCY, LXEO, DMAC, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	IPSC Century Therapeutics	-$0.11	N/A	N/A	N/A	$2.17 million	N/A
8/13/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.30	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	DMAC DiaMedica Therapeutics	-$0.2009	-$0.19	+$0.0109	-$0.19	$13.50 million	N/A
5/14/2026	Q1 2026	ONCY Oncolytics Biotech	-$0.05	-$0.08	-$0.03	-$0.08	N/A	N/A
5/13/2026	Q1 2026	IPSC Century Therapeutics	-$0.15	-$0.11	+$0.04	-$0.11	$2.87 million	N/A
5/11/2026	Q1 2026	LXEO Lexeo Therapeutics	-$0.29	-$0.25	+$0.04	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	9.11	9.11
IPSC Century Therapeutics	N/A	10.25	10.25
LXEO Lexeo Therapeutics	N/A	14.16	14.16
ONCY Oncolytics Biotech	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
IPSC Century Therapeutics	50.20%
LXEO Lexeo Therapeutics	60.67%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	5.00%
IPSC Century Therapeutics	2.40%
LXEO Lexeo Therapeutics	2.00%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	20	53.88 million	51.19 million	Optionable
IPSC Century Therapeutics	170	180.35 million	176.03 million	Optionable
LXEO Lexeo Therapeutics	58	78.52 million	76.95 million	Not Optionable
ONCY Oncolytics Biotech	30	119.35 million	119.24 million	Not Optionable

ONCY, LXEO, DMAC, and IPSC Headlines

Recent News About These Companies

Oncolytics Biotech (ONCY) to Post Earnings on Friday

August 7, 2026 | americanbankingnews.com

Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

August 7, 2026 | marketbeat.com

Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy?

July 31, 2026 | marketbeat.com

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

July 20, 2026 | globenewswire.com

ONCY: Seeking Registration Pathway for Part B of REO 033 Trial

July 16, 2026 | finance.yahoo.com

Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer

July 13, 2026 | quiverquant.comQ

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

July 13, 2026 | globenewswire.com

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

June 16, 2026 | tipranks.com

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

June 16, 2026 | globenewswire.com

Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention

June 5, 2026 | finance.yahoo.com

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

June 2, 2026 | globenewswire.com

ONCY stock heads for sixth straight session of gains – lead therapy shines in early combination treatment study

June 1, 2026 | msn.com

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

June 1, 2026 | globenewswire.com

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

May 22, 2026 | globenewswire.com

ONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancer

May 19, 2026 | msn.com

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

May 4, 2026 | globenewswire.com

Oncolytics Biotech, Inc.: Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

April 27, 2026 | finanznachrichten.de

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

April 27, 2026 | globenewswire.com

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

April 25, 2026 | seekingalpha.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)

April 12, 2026 | theglobeandmail.com

Oncolytics Plans FDA Meeting for Pelareorep SCAC Study

April 7, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, LXEO, DMAC, and IPSC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$7.11 +0.46 (+6.92%)

As of 02:54 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Century Therapeutics NASDAQ:IPSC

$2.04 +0.06 (+2.78%)

As of 02:54 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Lexeo Therapeutics NASDAQ:LXEO

$4.80 +0.18 (+3.78%)

As of 02:54 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Oncolytics Biotech NASDAQ:ONCY

$0.81 +0.00 (+0.40%)

As of 02:52 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, LXEO, DMAC, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, LXEO, DMAC, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, LXEO, DMAC, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, LXEO, DMAC, and IPSC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Century Therapeutics NASDAQ:IPSC

Lexeo Therapeutics NASDAQ:LXEO

Oncolytics Biotech NASDAQ:ONCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, LXEO, DMAC, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, LXEO, DMAC, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, LXEO, DMAC, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, LXEO, DMAC, and IPSC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Century Therapeutics NASDAQ:IPSC

Lexeo Therapeutics NASDAQ:LXEO

Oncolytics Biotech NASDAQ:ONCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools